HER2-targeted therapy-antibodies and beyond

被引：0

作者：

Fehm, Tanja ^{[1
]}

Mueller, Volkmar ^{[2
]}

机构：

[1] Univ Frauenklin Dusseldorf, Dusseldorf, Germany

[2] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Gynakol, Martinistr 52, D-20246 Hamburg, Germany

来源：

GYNAKOLOGE | 2021年 / 54卷 / 05期

关键词：

Breast cancer; Quality of life; Precision medicine; Enzyme inhibitors; Tyrosine kinases; METASTATIC BREAST-CANCER; TRASTUZUMAB EMTANSINE; MONOCLONAL-ANTIBODY; OPEN-LABEL; HER2; CHEMOTHERAPY; COMBINATION; PERTUZUMAB; DOCETAXEL; EFFICACY;

D O I：

10.1007/s00129-021-04789-2

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

With the development of the monoclonal antibody trastuzumab against HER2, a significant breakthrough was achieved in the treatment of primary and metastatic HER2-positive breast cancer. In the years that followed, dual blockade with the antibodies trastuzumab and pertuzumab in combination with taxane-containing chemotherapy resulted in a further significant improvement in both the metastatic and adjuvant treatment situation. T-DM1, which is an antibody drug conjugate built by attaching maytensin to the monoclonal antibody trastuzumab with a linker, has further increased survival in the metastatic situation after trastuzumab compared to the former second-line treatment standard capecitabine/lapatinib. In the postneoadjuvant setting T-DM1 is associated with a significant invasive disease-free survival benefit compared to maintaining therapy with trastuzumab. New drug developments include tyrosine kinase inhibitors such as neratinib and tucatenib as well as innovative antibody-drug conjugates including trastuzumab-deruxtecane.

引用

页码：320 / 328

页数：9

共 33 条

[1] Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 [J].

Abraham, Jame ;

Montero, Albert J. ;

Jankowitz, Rachel C. ;

Salkeni, Mohamad Adham ;

Beumer, Jan H. ;

Kiesel, Brian F. ;

Piette, Fanny ;

Adamson, Laura M. ;

Nagy, Rebecca J. ;

Lanman, Richard B. ;

Sperinde, Jeff ;

Huang, Weidong ;

Allegra, Carmen J. ;

Srinivasan, Ashok ;

Wang, Ying ;

Pogue-Geile, Katherine L. ;

Lucas, Peter C. ;

Jacobs, Samuel A. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) :2601-+

[2] Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [J].

Bachelot, T. ;

Ciruelos, E. ;

Schneeweiss, A. ;

Puglisi, F. ;

Peretz-Yablonski, T. ;

Bondarenko, I. ;

Paluch-Shimon, S. ;

Wardley, A. ;

Merot, J. -L. ;

du Toit, Y. ;

Easton, V. ;

Lindegger, N. ;

Miles, D. ;

Bouzid, Kamel ;

Campone, Mario ;

Coudert, Bruno ;

Nowecki, Zbigniew ;

Errihani, Hassan ;

Dalenc, Florence ;

Ferreira, Ana ;

Mano, Max ;

Ricci, Francesco ;

Kalofonos, Haralabos ;

Andreetta, Claudia ;

Montemurro, Filippo ;

Barrett, Sophie ;

Zhang, Qingyuan ;

Mavroudis, Dimitris ;

Matus, Juan ;

Beato, Carlos ;

Hu, Xichun ;

Gaafar, Rabab ;

Azeem, Hamdy Abdel ;

Perrin, Christophe ;

Ettl, Johannes ;

Lang, Istvan ;

Verma, Sunil ;

Li, Huiping ;

Brain, Etienne ;

Hoffmann, Oliver ;

Cariello, Anna ;

Tondini, Carlo ;

Altwegeiri, Taher ;

Loman, Niklas ;

Lux, Michael ;

Frassoldati, Antonio ;

Aziz, Zeba ;

Salas, Fernando ;

Streb, Joanna ;

Wronski, Andrzej .

ANNALS OF ONCOLOGY, 2019, 30 (05) :766-773

[3] First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors [J].

Bang, Y. J. ;

Giaccone, G. ;

Im, S. A. ;

Oh, D. Y. ;

Bauer, T. M. ;

Nordstrom, J. L. ;

Li, H. ;

Chichili, G. R. ;

Moore, P. A. ;

Hong, S. ;

Stewart, S. J. ;

Baughman, J. E. ;

Lechleider, R. J. ;

Burris, H. A. .

ANNALS OF ONCOLOGY, 2017, 28 (04) :855-861

[4] Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope S. ;

Sledge, George ;

Aktan, Gursel ;

Ellis, Catherine ;

Florance, Allison ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2585-2592

[5] Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-PositiveMetastatic Breast Cancer A Phase 1b Clinical Trial [J].

Borges, Virginia F. ;

Ferrario, Cristiano ;

Aucoin, Nathalie ;

Falkson, Carla ;

Khan, Qamar ;

Krop, Ian ;

Welch, Stephen ;

Conlin, Alison ;

Chaves, Jorge ;

Bedard, Philippe L. ;

Chamberlain, Marc ;

Gray, Todd ;

Vo, Alex ;

Hamilton, Erika .

JAMA ONCOLOGY, 2018, 4 (09) :1214-1220

[6] Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial [J].

Chan, Arlene ;

Moy, Beverly ;

Mansi, Janine ;

Ejlertsen, Bent ;

Holmes, Frankie Ann ;

Chia, Stephen ;

Iwata, Hiroji ;

Gnant, Michael ;

Loibl, Sibylle ;

Barrios, Carlos H. ;

Somali, Isil ;

Smichkoska, Snezhana ;

Martinez, Noelia ;

Alonso, Mirta Garcia ;

Link, John S. ;

Mayer, Ingrid A. ;

Cold, Soren ;

Murillo, Serafin Morales ;

Senecal, Francis ;

Inoue, Kenichi ;

Ruiz-Borrego, Manuel ;

Hui, Rina ;

Denduluri, Neelima ;

Patt, Debra ;

Rugo, Hope S. ;

Johnston, Stephen R. D. ;

Bryce, Richard ;

Zhang, Bo ;

Xu, Feng ;

Wong, Alvin ;

Martin, Miguel .

CLINICAL BREAST CANCER, 2021, 21 (01) :80-+

[7]

Fehm T, 2020, ONKOLOGE, V26, P518, DOI 10.1007/s00761-020-00724-7

[8]

FREEDMAN R, 2019, CLIN BREAST CANCER

[9] Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial [J].

Huober, J. ;

Fasching, P. A. ;

Barsoum, M. ;

Petruzelka, L. ;

Wallwiener, D. ;

Thomssen, C. ;

Reimer, T. ;

Paepke, S. ;

Azim, H. A. ;

Ragosch, V. ;

Kubista, E. ;

Baumgaertner, A. K. ;

Beckmann, M. W. ;

May, C. ;

Nimmrich, I. ;

Harbeck, N. .

BREAST, 2012, 21 (01) :27-33

[10] Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer [J].

Johnston, Stephen ;

Pippen, John, Jr. ;

Pivot, Xavier ;

Lichinitser, Mikhail ;

Sadeghi, Saeed ;

Dieras, Veronique ;

Gomez, Henry Leonidas ;

Romieu, Gilles ;

Manikhas, Alexey ;

Kennedy, M. John ;

Press, Michael F. ;

Maltzman, Julie ;

Florance, Allison ;

O'Rourke, Lisa ;

Oliva, Cristina ;

Stein, Steven ;

Pegram, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5538-5546

← 1 2 3 4 →